BeiGene, Ltd. (BGNE)
294.70 0.00 (0.00%)
After hours: 4:40PM EST
| Previous close | 301.28 |
| Open | 296.85 |
| Bid | 294.52 x 800 |
| Ask | 301.28 x 800 |
| Day's range | 287.22 - 300.64 |
| 52-week range | 118.55 - 388.97 |
| Volume | 513,038 |
| Avg. volume | 348,111 |
| Market cap | 25.98B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -19.13 |
| Earnings date | 07 Aug 2018 - 13 Aug 2018 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 320.58 |
- Business Wire
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that a supplemental Biologics License Application (sBLA) for anti-PD1 antibody tislelizumab was accepted by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for treatment in the second- or third-line setting of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on prior platinum-based chemotherapy.
- Business Wire
Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia
Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia
- Simply Wall St.
BeiGene, Ltd. (NASDAQ:BGNE) Analysts Just Slashed This Year's Revenue Estimates By 33%
Market forces rained on the parade of BeiGene, Ltd. ( NASDAQ:BGNE ) shareholders today, when the analysts downgraded...
